AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38658017 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular classification
Number of subjects: 223
Study 38658017 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 abnormality
Number of subjects: 223
Study 38658024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib, Tislelizumab, Bevacizumab, and Nab-Paclitaxel (biomarker-driven combinatorial therapies)
Number of subjects: 160
Study 38658101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 19220
Study 38658101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19220
Study 38658126 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR
Number of subjects: 1584
Study 38658126 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1584
Study 38658128 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1863
Study 38658392 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel PSMA-targeting radionuclide therapy agents
Number of subjects: 0
Study 38658398 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-rich kindergarten meals (2-week meal plan including breakfast, lunch, and two snacks)
Number of subjects: 57
Study 38658398 — intervention group
Group type: COMPARATOR
Intervention: Standard kindergarten meal plans (control group)
Number of subjects: 57
Study 38658398 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-rich kindergarten meals
Number of subjects: 57
Study 38658485 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 440
Study 38658485 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNFα agents
Number of subjects: 440
Study 38658485 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (top 40% effect score distribution)
Number of subjects: 440
Study 38658485 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNFα agents (top 40% effect score distribution)
Number of subjects: 440
Study 38658775 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous HER2-specific CAR T cells after lymphodepletion with fludarabine (Flu) ± cyclophosphamide (Cy)
Number of subjects: 0
Study 38658877 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (2 mg and 5 mg)
Number of subjects: 0
Study 38658877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38659046 — intervention group
Group type: EXPERIMENTAL
Intervention: LCAR-B38M CAR T-cell therapy
Number of subjects: 74
Study 38659046 — intervention group
Group type: COMPARATOR
Intervention: Subsequent therapies after PD
Number of subjects: 74
Study 38659187 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygenation at flow rates of 50-60 L/min
Number of subjects: 0
Study 38659187 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38659226 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncolytic adenovirus H101
Number of subjects: 25
Study 38659226 — intervention group
Group type: COMPARATOR
Intervention: Control value
Number of subjects: 25
Study 38659334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg up to once per day as EOD + PRN for 12 weeks
Number of subjects: 1800
Study 38659334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant PRN for up to 52 weeks
Number of subjects: 1800
Study 38659334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant (overall)
Number of subjects: 1800
Study 38659874 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led SBIRT intervention plus Alive!
Number of subjects: 440
Study 38659874 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm (CRC prevention educational pamphlets and a list of CRC screening sites)
Number of subjects: 440
Study 38660060 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glucose eating (LGE)
Number of subjects: 17
Study 38660112 — intervention group
Group type: EXPERIMENTAL
Intervention: Men undergoing TAVR
Number of subjects: 0
Study 38660112 — intervention group
Group type: EXPERIMENTAL
Intervention: Women undergoing TAVR
Number of subjects: 0
Study 38660112 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian cohort (Men)
Number of subjects: 0
Study 38660112 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian cohort (Women)
Number of subjects: 0
Study 38660112 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Asian cohort (Men)
Number of subjects: 0
Study 38660112 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Asian cohort (Women)
Number of subjects: 0
Study 38660276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1
Number of subjects: 140
Study 38660371 — intervention group
Group type: EXPERIMENTAL
Intervention: Group phone calls (GP)
Number of subjects: 0
Study 38660371 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual phone calls (IP)
Number of subjects: 0
Study 38660371 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 0
Study 38660371 — intervention group
Group type: COMPARATOR
Intervention: Individual phone calls (IP) vs Enhanced usual care (EUC)
Number of subjects: 0
Study 38660518 — intervention group
Group type: EXPERIMENTAL
Intervention: Active human MMP9 (act-hMMP9)
Number of subjects: 31
Study 38660518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 38660794 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 419
Study 38660794 — intervention group
Group type: COMPARATOR
Intervention: FFR-guided PCI
Number of subjects: 419
Study 38660794 — intervention group
Group type: EXPERIMENTAL
Intervention: μQFR
Number of subjects: 419
Study 38661071 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 6
Study 38661180 — intervention group
Group type: COMPARATOR
Intervention: Proactive screening algorithm for early-onset pneumonia (EOP) implemented in study period 2.
Number of subjects: 190
Study 38661449 — intervention group
Group type: EXPERIMENTAL
Intervention: Exagamglogene autotemcel (exa-cel)
Number of subjects: 44
Study 38661512 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study 38661602 — intervention group
Group type: EXPERIMENTAL
Intervention: AGN-151607 125 U
Number of subjects: 312
Study 38661602 — intervention group
Group type: EXPERIMENTAL
Intervention: AGN-151607 250 U
Number of subjects: 312
Study 38661602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 38661649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (TRACK)
Number of subjects: 0
Study 38661677 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 17
Study 38662147 — intervention group
Group type: EXPERIMENTAL
Intervention: Emapalumab 1 mg/kg (increasing to 3, 6, and up to 10 mg/kg based on clinical response) every 3 days for primary HLH
Number of subjects: 58
Study 38662147 — intervention group
Group type: EXPERIMENTAL
Intervention: Emapalumab 6 mg/kg followed by 3 mg/kg every 3 days until day 15 and twice weekly until day 28 for MAS in sJIA
Number of subjects: 58
Study 38662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (probiotics and inulin prebiotics)
Number of subjects: 90
Study 38662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 90
Study 38662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics and Probiotics
Number of subjects: 90
Study 38662232 — intervention group
Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 90
Study 38662232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 38662300 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic deep brain stimulation (STN-DBS)
Number of subjects: 35
Study 38662318 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV)
Number of subjects: 0
Study 38662318 — intervention group
Group type: COMPARATOR
Intervention: Placebo (unvaccinated)
Number of subjects: 0
Study 38662320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglionic local opioid analgesia (GLOA) at the superior cervical ganglion with a total volume of 2 ml injected into the parapharyngeal space and its 'medial compartment'.
Number of subjects: 0
Study 38662320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglionic local opioid analgesia (GLOA) at the superior cervical ganglion.
Number of subjects: 0
Study 38662364 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pelvic radiation using hypofractionated IMRT with 40 Gy in 16 fractions combined with concurrent chemotherapy
Number of subjects: 79
Study 38662373 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 overprescribing warning letters
Number of subjects: 346169
Study 38662373 — intervention group
Group type: COMPARATOR
Intervention: Placebo letter
Number of subjects: 346169
Study 38662372 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg IV, max 1000 mg)
Number of subjects: 509
Study 38662372 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified higher-dose regimen of abatacept
Number of subjects: 509
Study 38662520 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized ACP conversation and summarizing palliative plan
Number of subjects: 144
Study 38662520 — intervention group
Group type: COMPARATOR
Intervention: No organized ACP conversation and summarizing palliative plan
Number of subjects: 144
Study 38662639 — intervention group
Group type: EXPERIMENTAL
Intervention: SHEN26
Number of subjects: 86
Study 38662639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 38662661 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Observation intervention
Number of subjects: 0
Study 38662661 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 0
Study 38662661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 0
Study 38662712 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary screening tool (27-item FFQ)
Number of subjects: 58
Study 38662736 — intervention group
Group type: EXPERIMENTAL
Intervention: Basis pursuit denoising with polynomial detrending (BPWP) model
Number of subjects: 3
Study 38662779 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) adherence measured over 95 days
Number of subjects: 33
Study 38662779 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) adherence for hemorrhagic events
Number of subjects: 33
Study 38662779 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC) adherence for ischemic events
Number of subjects: 33
Study 38662779 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing adherence
Number of subjects: 33
Study 38662979 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium 10 mg
Number of subjects: 268
Study 38662979 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium 30 mg
Number of subjects: 268
Study 38662979 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium 45 mg
Number of subjects: 268
Study 38662979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 38662979 — intervention group
Group type: EXPERIMENTAL
Intervention: Any dose of vidofludimus calcium
Number of subjects: 268
Study 38662991 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib 560 mg and venetoclax 400 mg once daily
Number of subjects: 24
Study 38662991 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective treatment interruption (ETI) for patients in MRD-negative CR
Number of subjects: 24
Study 38662991 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment after disease recurrence
Number of subjects: 24
Study 38662991 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-to-treatment failure (TTF)
Number of subjects: 24
Study 38662991 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with venetoclax-ibrutinib
Number of subjects: 24
Study 38663455 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN + NAs
Number of subjects: 196
Study 38663455 — intervention group
Group type: COMPARATOR
Intervention: NAs
Number of subjects: 196
Study 38663455 — intervention group
Group type: EXPERIMENTAL
Intervention: New scoring system
Number of subjects: 196
Study 38663470 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 2281
Study 38663470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2281
Study 38663539 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 1.5 mg (LNG1X)
Number of subjects: 488
Study 38663539 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 3.0 mg (LNG2X)
Number of subjects: 488
Study 38663539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate 30 mg (UPA)
Number of subjects: 488
Study 38663582 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised, escalated fraction dose of radiotherapy (24 x 3.0-5.4 Gy) with either sequential or concurrent chemoradiotherapy, or radiotherapy only.
Number of subjects: 102
Study 38663582 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail, but implied to be standard treatment without dose escalation).
Number of subjects: 102
Study 38663902 — intervention group
Group type: EXPERIMENTAL
Intervention: Days with moderate to severe headache
Number of subjects: 720
Study 38663902 — intervention group
Group type: EXPERIMENTAL
Intervention: Days with mild headache
Number of subjects: 720
Study 38663902 — intervention group
Group type: EXPERIMENTAL
Intervention: Days with no headache
Number of subjects: 720
Study 38663903 — intervention group
Group type: EXPERIMENTAL
Intervention: ICHD-3 criteria for idiopathic intracranial hypertension headache
Number of subjects: 0
Study 38663908 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 86
Study 38663950 — intervention group
Group type: EXPERIMENTAL
Intervention: Total carrageenans (100 mg per day)
Number of subjects: 104139
Study 38663950 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenans gum (E407, 100 mg per day)
Number of subjects: 104139
Study 38663950 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium phosphate (E340, 500 mg per day)
Number of subjects: 104139
Study 38663950 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl tartaric acid esters of monoglycerides and diglycerides of fatty acids (E472e, 100 mg per day)
Number of subjects: 104139
Study 38663950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (E331, 500 mg per day)
Number of subjects: 104139
Study 38663950 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (E412, 500 mg per day)
Number of subjects: 104139
Study 38663950 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum arabic (E414, 1000 mg per day)
Number of subjects: 104139
Study 38663950 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthan gum (E415, 500 mg per day)
Number of subjects: 104139
Study 38664002 — intervention group
Group type: EXPERIMENTAL
Intervention: VLNC messages (n=468)
Number of subjects: 971
Study 38664002 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette messages (n=484)
Number of subjects: 971
Study 38664002 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined VLNC and e-cigarette messages (n=476)
Number of subjects: 971
Study 38664002 — intervention group
Group type: COMPARATOR
Intervention: Control condition (water ads, n=473)
Number of subjects: 971
Study 38664002 — intervention group
Group type: EXPERIMENTAL
Intervention: VLNC messages (n=468) among adults who dual used
Number of subjects: 971
Study 38664019 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific membrane antigen (PSMA) PET/CT before definitive radiotherapy
Number of subjects: 0
Study 38664019 — intervention group
Group type: COMPARATOR
Intervention: Definitive radiotherapy
Number of subjects: 0
Study 38664311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled, autologous temporoparietal fascial flap (TPFF) or pericranial flap (PCF) lining the resection cavity after maximal surgical resection of GBM.
Number of subjects: 12
Study 38664311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled, autologous TPFF/PCF lining the resection cavity after maximal surgical resection of GBM.
Number of subjects: 12
Study 38664404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 0
Study 38664577 — intervention group
Group type: COMPARATOR
Intervention: FLOX regimen (control group)
Number of subjects: 80
Study 38664577 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating two cycles of FLOX and nivolumab (experimental group)
Number of subjects: 80
Study 38664620 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal primary prevention programme (n=127)
Number of subjects: 255
Study 38664620 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=128)
Number of subjects: 255
Study 38664665 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced study arm with Boot Camp Translation (BCT) materials
Number of subjects: 82
Study 38664665 — intervention group
Group type: COMPARATOR
Intervention: Non-local materials
Number of subjects: 82
Study 38664701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led education according to the AR-PRISE model
Number of subjects: 154
Study 38664701 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceutical care
Number of subjects: 154
Study 38664706 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude ratio variables (ln[affected side magnitude/less-affected side magnitude])
Number of subjects: 0
Study 38664706 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical clustering analysis
Number of subjects: 0
Study 38664706 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component 2 (magnitude ratio domain)
Number of subjects: 0
Study 38664706 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component 1 (activity time and distance component)
Number of subjects: 0
Study 38664715 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids SIPsmartER intervention
Number of subjects: 526
Study 38664715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 526
Study 38664766 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus corticosteroids (5 mg/m2 methotrexate)
Number of subjects: 157
Study 38664766 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone (control group)
Number of subjects: 157
Study 38664809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor barrier with active heating source
Number of subjects: 16
Study 38664809 — intervention group
Group type: COMPARATOR
Intervention: Control (without vapor barrier)
Number of subjects: 16
Study 38664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic flexion to extension cinematographic recordings of the cervical spine (T1 and T2 recordings with a 2-to-4-week interval)
Number of subjects: 10
Study 38664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental range of motion (sRoM) and total range of motion (tRoM) measurements
Number of subjects: 10
Study 38664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis between sagittal alignment, degeneration and sRoM
Number of subjects: 10
Study 38664811 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis between cervical lordosis and tRoM
Number of subjects: 10
Study 38664919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 (default bias and implementation intention)
Number of subjects: 229
Study 38664919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 (availability bias and social norm)
Number of subjects: 229
Study 38664919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 229
Study 38664919 — intervention group
Group type: EXPERIMENTAL
Intervention: General finding
Number of subjects: 229
Study 38665252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination naltrexone (NTX) and oral bupropion (BUP)
Number of subjects: 403
Study 38665252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 38665302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mango Leaf Extract (MLE) 300 mg
Number of subjects: 114
Study 38665302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 38665614 — intervention group
Group type: EXPERIMENTAL
Intervention: Younis multivariate score (low score ≤14)
Number of subjects: 292
Study 38665614 — intervention group
Group type: COMPARATOR
Intervention: Younis multivariate score (high score >14)
Number of subjects: 292
Study 38665889 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable devices monitoring in the more severe group
Number of subjects: 98
Study 38665889 — intervention group
Group type: COMPARATOR
Intervention: Wearable devices monitoring in the milder group
Number of subjects: 98
Study 38665889 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring heart rate-related parameters post-discharge
Number of subjects: 98
Study 38666065 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study 38666065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38666252 — intervention group
Group type: EXPERIMENTAL
Intervention: High IFABP group (75th percentile)
Number of subjects: 50
Study 38666252 — intervention group
Group type: COMPARATOR
Intervention: Low IFABP group (25th percentile)
Number of subjects: 50
Study 38666252 — intervention group
Group type: EXPERIMENTAL
Intervention: Effects through IL-6
Number of subjects: 50
Study 38666789 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver group
Number of subjects: 106
Study 38666789 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 38668005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care foams
Number of subjects: 0
Study 38668005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care spray
Number of subjects: 0
Study 38668005 — intervention group
Group type: COMPARATOR
Intervention: Control (no oral care product)
Number of subjects: 0
Study 38668642 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional deep brain stimulation (DBS) of the VP thalamus
Number of subjects: 6
Study 38668732 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused nurse-led postdischarge intervention
Number of subjects: 110